Literature DB >> 12393412

Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma.

Justine R Smith1, Rita M Braziel, Samantha Paoletti, Martin Lipp, Mariagrazia Uguccioni, James T Rosenbaum.   

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare but often rapidly fatal form of non-Hodgkin B-cell lymphoma that arises within the central nervous system (CNS) and has a low propensity to metastasize. We performed immunohistochemistry on formalin-fixed, paraffin-embedded brain biopsy specimens from 24 patients with PCNSL to investigate the expression of B cell-attracting chemokine 1 (BCA-1, CXCL13), a lymphoid chemokine involved in B-cell compartmental homing within secondary lymphoid organs and recently implicated in the pathogenesis of inflammatory and malignant lymphocyte-mediated diseases. Whereas BCA-1 was not detected in normal human brain, all 24 brain biopsy specimens containing PCNSL were positive for BCA-1. Double immunostaining on selected specimens localized BCA-1 to malignant B lymphocytes and vascular endothelium. In contrast, 2 chemokines implicated particularly in T-cell movement, secondary lymphoid tissue chemokine (SLC, CCL21) and Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC, CCL19), were expressed only by occasional stromal cells in 2 and 4 of the 24 specimens, respectively. Tumor cells stained positively for CXCR5, the primary receptor for BCA-1. In situ hybridization verified the expression of BCA-1 mRNA by malignant B cells, but not vascular endothelium, within the tumor mass, suggesting that vascular endothelial BCA-1 expression may be consequent to transcytosis. In PCNSL, expression of BCA-1 by malignant lymphocytes and vascular endothelium may influence tumor development and localization to CNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393412     DOI: 10.1182/blood-2002-05-1576

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

Review 1.  Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.

Authors:  Chi-Chao Chan; James L Rubenstein; Sarah E Coupland; Janet L Davis; J William Harbour; Patrick B Johnston; Nathalie Cassoux; Valerie Touitou; Justine R Smith; Tracy T Batchelor; Jose S Pulido
Journal:  Oncologist       Date:  2011-11-01

Review 2.  Biology and treatment of primary central nervous system lymphoma.

Authors:  Alain P Algazi; Cigall Kadoch; James L Rubenstein
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 3.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 4.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 5.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

Review 6.  The Eyes Have it: A Rheumatologist's View of Uveitis.

Authors:  James T Rosenbaum; Andrew D Dick
Journal:  Arthritis Rheumatol       Date:  2018-08-23       Impact factor: 10.995

7.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

8.  Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.

Authors:  Zhuqing Li; Sankaranarayana P Mahesh; De Fen Shen; Baoying Liu; Willie O Siu; Frank S Hwang; Qing-Chen Wang; Chi-Chao Chan; Ira Pastan; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

9.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

10.  Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-hodgkin B-cell lymphoma risk.

Authors:  Shehnaz K Hussain; Weiming Zhu; Shen-Chih Chang; Elizabeth Crabb Breen; Elena Vendrame; Larry Magpantay; Dan Widney; Daniel Conn; Mary Sehl; Lisa P Jacobson; Jay H Bream; Steven Wolinsky; Charles R Rinaldo; Richard F Ambinder; Roger Detels; Zuo-Feng Zhang; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-18       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.